<DOC>
	<DOC>NCT02145351</DOC>
	<brief_summary>Determine the impact of restoring normal heart rate response during exercise and daily activity in patients with heart failure and a preserved ejection fraction (HFpEF) and chronotropic incompetence (CI).</brief_summary>
	<brief_title>Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure, Diastolic</mesh_term>
	<criteria>Inclusion Criteria 1. Age &gt;18 years and able to provide informed consent to enroll in the trial, or consent through a legal guardian or power of attorney. 2. Previous clinical diagnosis of HF with current NYHA Class IIIII symptoms 3. At least one of the following: Hospitalization for decompensated HF, Acute treatment for HF with intravenous loop diuretic or hemofiltration, Chronic treatment with a loop diuretic for control of HF symptoms + left atrial enlargement on echocardiography 4. Left ventricular EF ≥50% within 12 months with clinical stability 5. Stable cardiac medical therapy for ≥30 days 6. Sinus rhythm 7. Chronotropic incompetence on recent (within 6 months) clinical or screening exercise test, defined as heart rate reserve (HRR) &lt;0.80 8. Meet both screening criteria on clinicallyperformed cardiopulmonary exercise testing within 12 months. Peak VO2 ≤60% age/sexadjusted normal value + peak respiratory exchange ratio (RER) ≥1.05 One of the following: NTproBNP ≥400 pg/mL or NTproBNP &lt;400 pg/mL, with rest PCWP &gt;20 mmHg and/or &gt;25 mmHg with exercise Exclusion Criteria 1. Inability to exercise, or noncardiac condition that precludes exercise testing 2. Any contraindication to a pacemaker system 3. Noncardiac condition limiting life expectancy to less than one year 4. Significant left sided structural valve disease (&gt;mild stenosis, &gt;moderate regurgitation) 5. Hypertrophic cardiomyopathy 6. Infiltrative or inflammatory myocardial disease (amyloid, sarcoid) 7. Pericardial disease 8. Nongroup 2 pulmonary arterial hypertension 9. Chronic stable exertional angina 10. Acute coronary syndrome or revascularization within 60 days 11. Other clinically important causes of dyspnea 12. Atrial fibrillation 13. PR interval &gt;210 msec 14. Resting heart rate (HR) &gt; 100 bpm 15. A history of reduced ejection fraction (EF&lt;50%) 16. Advanced chronic kidney disease (GFR &lt; 20 ml/min/1.73m2 by modified MDRD equation) 17. Women of child bearing potential without negative pregnancy test and effective contraception 18. Severe anemia (Hemoglobin &lt;10 g/dL) 19. Severe hepatic disease 20. Complex congenital heart disease 21. Listed for cardiac transplantation 22. Other class I indications for pacing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HFpEF</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Heart failure with preserved ejection fraction</keyword>
	<keyword>Chronotropic incompetence</keyword>
</DOC>